Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
Status:
Terminated
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to compare the safety and efficacy of a single dose of
Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA)
to our standard four dose, four day Thymoglobulin induction regimen from the time of
transplantation through a six month follow-up period. The primary endpoint will be the
incidence of acute rejection. Secondary endpoints will include serious adverse events,
evaluation of renal function, patient and graft survival, incidence of infectious
complications, incidence of post-transplantation lymphoproliferative disorder (PTLD),
duration and extent of lymphocyte depletion and immunoassays for evidence of recipient immune
response to the allograft as well as duration of hospital stay.